ライフサイエンスコーパス: brain metastasis

1 intracranial control following resection of brain metastasis.

2 compared with WBRT in patients with resected brain metastasis.

3 nase in vitro cell invasion and experimental brain metastasis.

4 knowledge of the initial events that lead to brain metastasis.

5 with breast cancer, 362 developed subsequent brain metastasis.

6 and independently associated with subsequent brain metastasis.

7 m could prove valuable for the inhibition of brain metastasis.

8 s, which served as a proxy for an orthotopic brain metastasis.

9 n contrast, ST6GALNAC5 specifically mediates brain metastasis.

10 is of melanoma cells, consequently promoting brain metastasis.

11 al cues at the BBB affects the mechanisms of brain metastasis.

12 cases, 5/5 meningioma cases and 3/3 cases of brain metastasis.

13 s and treatment response in CNS lymphoma and brain metastasis.

14 be uniquely suited to the local treatment of brain metastasis.

15 ival for patients with a single unresectable brain metastasis.

16 ages in 23 patients disclosed no evidence of brain metastasis.

17 nt immune response can eliminate established brain metastasis.

18 tial for study of the biology and therapy of brain metastasis.

19 r mechanisms of angiogenesis in experimental brain metastasis.

20 ich significantly decreased the incidence of brain metastasis.

21 y correlated with angiogenesis and growth of brain metastasis.

22 t during metastatic evolution is crucial for brain metastasis.

23 an experimental mouse model of breast cancer brain metastasis.

24 pe in the brain, the astrocyte, in promoting brain metastasis.

25 ese drugs could be used to treat established brain metastasis.

26 RCC with vascular invasion, liver, lung and brain metastasis.

27 therapy can inhibit growth of breast cancer brain metastasis.

28 anged non-small-cell lung cancer (NSCLC) and brain metastasis.

29 n and recruitment of myeloid cell to promote brain metastasis.

30 tic target or serve as a prognostic tool for brain metastasis.

31 eural effusion and pericardial effusion; and brain metastasis.

32 able therapeutic platform to target melanoma brain metastasis.

33 enges in the development of therapeutics for brain metastasis.

34 d MET attenuation decreased the incidence of brain metastasis.

35 rvention of MMP-2-dependent diseases such as brain metastasis.

36 t patients with breast cancer suffering from brain metastasis.

37 presents a potential target for treatment of brain metastasis.

38 R2 signaling for HER2-positive breast cancer brain metastasis.

39 hanistic and therapeutic studies of melanoma brain metastasis.

40 Additional imaging showed no brain metastasis.

41 ted vessels in two separate murine models of brain metastasis.

42 In a syngeneic model of melanoma brain metastasis, a combination of MSC-oHSV and PD-L1 bl

43 is a novel prognostic marker for lung and/or brain metastasis and a predictive marker for the respons

44 ions in the USA and Canada with one resected brain metastasis and a resection cavity less than 5.0 cm

45 cer: peripheral blood, the primary tumour, a brain metastasis and a xenograft derived from the primar

46 terface in 26 patients during resection of a brain metastasis and assessed mean diffusivity and fract

47 ment for patients with a single unresectable brain metastasis and considered for patients with two or

48 we developed a model to study human melanoma brain metastasis and found that Stat3 activity was incre

49 hting its role as a double agent in limiting brain metastasis and its local consequences.

50 ical metabolic condition required to sustain brain metastasis and suggest that targeting gluconeogene

51 ary but not sufficient for the production of brain metastasis and that the inhibition of VEGF represe

52 These patients were free of brain metastasis and underwent standard treatment and su

53 re also associated with development of NSCLC brain metastasis and were selectively enriched in brain

54 asis (BCBM) may allow for early diagnosis of brain metastasis and/or help for treatment choice and it

55 mately 50% of patients with melanoma develop brain metastasis, and currently there are no beneficial

56 metabolism is a key element in breast cancer brain metastasis, and raise the possibility of targeting

57 Coupling whole tissue imaging of brain metastasis animal models with SMART 3D, we demonst

58 iologic and therapeutic advances in melanoma brain metastasis are hampered by the paucity of reproduc

59 The current animal models for brain metastasis are highly variable, leading to a need

60 his increased Stat3 activation and effect on brain metastasis are unknown.

61 45 prostate cells, originally derived from a brain metastasis, are not responsive to PDGF.

62 ain metastases and data from an experimental brain metastasis assay, both indicative of a functional

63 blished a human breast cancer cell model for brain metastasis based on circulating tumor cells from a

64 anding of CTCs associated with breast cancer brain metastasis (BCBM) is necessary for early identific

65 TCs derived from breast cancer patients with brain metastasis (BCBM) may allow for early diagnosis of

66 ts had at least one untreated or progressive brain metastasis between 5 and 20 mm in diameter without

67 Brain metastasis (BM) is a leading cause of death from n

68 Brain metastasis (BM) is a major cause of suffering and

69 The incidence of brain metastasis (BM) was evaluated with the logistic re

70 cally in the intracardially induced model of brain metastasis but with lower sensitivity because of s

71 als cellular events during the initiation of brain metastasis by breast cancer cells and documents th

72 onal in LUAD and show that astrocytes oppose brain metastasis by mediating the downregulation of TRPA

73 ates the blood-brain barrier, could suppress brain metastasis by targeting c-Met signaling.

74 rostate cancer cell line, originating from a brain metastasis, carries a truncating mutation of EPHB2

75 of brain metastasis (P = 0.02) and a shorter brain metastasis-free survival in lymph node-negative pa

76 uced MMP9 were significantly correlated with brain metastasis-free survival of breast cancer patients

77 FET) PET for differentiating local recurrent brain metastasis from radiation necrosis after radiation

78 One patient with occult brain metastasis had grade 4 intracranial hemorrhage.

79 Primary brain tumor or brain metastasis (HR 2.5; P = .002), number of falls in

80 Studying spontaneous melanoma brain metastasis in a clinically relevant setting is the

81 as associated with metastatic progression to brain metastasis in a mouse xenograft model.

82 ritical role for Src activation in promoting brain metastasis in a preclinical model of breast cancer

83 astatic A375Br cells significantly inhibited brain metastasis in animal models (P<0.001).

84 as been implicated as an important driver of brain metastasis in breast cancer, but the critical targ

85 transplantable model of spontaneous melanoma brain metastasis in immunocompetent mice and developed m

86 e a unifying mechanism for the initiation of brain metastasis in lung and breast cancers.

87 bust tool that is able to predict subsequent brain metastasis in patients with breast cancer with non

88 Plasmin suppresses brain metastasis in two ways: by converting membrane-bou

89 ived cells showed an increased potential for brain metastasis in vivo and exhibited a unique protein

90 metabolic pathway decreased the incidence of brain metastasis in vivo Taken together, our results sho

91 cretion rescues the PTEN loss and suppresses brain metastasis in vivo.

92 Brain metastasis is a frequent occurrence in patients wi

93 Brain metastasis is a major cause of morbidity and morta

94 Brain metastasis is an end stage in breast cancer progre

95 Brain metastasis is an important cause of mortality in b

96 Brain metastasis is an ominous complication of cancer, y

97 etal imaging may be indicated if an isolated brain metastasis is detected.

98 bility to be more inclusive of patients with brain metastasis is justified in many cases and may spee

99 survival time of breast cancer patients with brain metastasis is less than 6 months, and even a small

100 Brain metastasis is one of the chief causes of mortality

101 nical importance, the molecular basis of the brain metastasis is poorly understood.

102 Breast cancer brain metastasis is resistant to therapy and a particula

103 The incidence of brain metastasis is rising and poses a severe clinical p

104 A key event during brain metastasis is the migration of cancer cells throug

105 Brain metastasis is the most commonly occurring intracra

106 PURPOSE Brain metastasis is usually a fatal event in patients wi

107 inflammatory response has been documented in brain metastasis, its contribution to cancer progression

108 d quantify volumetric and spatial aspects of brain metastasis landscapes, including diverse tumor mor

109 In vivo, in a model of brain metastasis, low or high Her-2-overexpressing 231-B

110 tic phenotype with the unusual occurrence of brain metastasis, making it an important target for diag

111 hese data suggest that the glial response to brain metastasis may provide a sensitive biomarker of tu

112 adiosurgery group for patients with a single brain metastasis (median survival time 6.5 vs 4.9 months

113 these results indicate a novel mechanism of brain metastasis mediated by EVs that triggers the destr

114 Herein, we describe an experimental brain metastasis model that uses ultrasonographic guidan

115 Using an experimental brain metastasis model, we characterized the brain metas

116 ecycling of GI-101A cells in an experimental brain metastasis model.

117 Characterizing clinically relevant brain metastasis models and assessing the therapeutic ef

118 stemic delivery of OV, we developed melanoma brain metastasis models in immunocompromised and immunoc

119 In cell-based culture and brain metastasis models, we found that downregulation of

120 ave developed an in vivo imageable breast-to-brain metastasis mouse model.

121 Brain metastasis occurred as the sole site of first fail

122 Brain metastasis occurs in 20-40% of cancer patients.

123 rats with HER2-positive cells derived from a brain metastasis of a breast cancer patient (MDA-MB-361)

124 suggest that miR-509 has a critical role in brain metastasis of breast cancer by modulating the RhoC

125 metastatic cancer cell-derived EVs promoted brain metastasis of breast cancer cell lines and are pre

126 In contrast, the calculated pore size of a brain metastasis of breast cancer was approximately 10-f

127 rve as biomarkers or therapeutic targets for brain metastasis of breast cancer.

128 l possesses the unique capability to examine brain metastasis of human lung, breast and melanoma cell

129 on with a dominant-negative Stat3 suppressed brain metastasis of human melanoma cells in animal model

130 an brain metastatic cells and contributes to brain metastasis of melanoma.

131 nvasion of melanoma cells and contributes to brain metastasis of melanoma.

132 R2 signaling for HER2-positive breast cancer brain metastasis.Oncogene advance online publication, 24

133 Brain metastasis only group and multiple sites metastasi

134 and < .001, respectively), whereas a single brain metastasis or initial treatment with SRS versus WB

135 ode status, along with a higher incidence of brain metastasis (P = 0.02) and a shorter brain metastas

136 sis therapies, especially of consequence for brain metastasis patients.

137 In patients with brain metastasis, PET using labeled amino acids has gain

138 In 29% of patients, the cause of death was brain metastasis progression.

139 of the 2 patients, subsequent resection of a brain metastasis proved HER2-positive disease, confirmin

140 time-activity curve can differentiate local brain metastasis recurrence from radionecrosis with high

141 The molecular changes that lead to brain metastasis remain poorly understood.

142 Brain metastasis represents a substantial source of morb

143 Thus, the use of SRS after brain metastasis resection could be an alternative to wh

144 After brain metastasis resection, whole brain radiotherapy dec

145 The primary endpoint was brain metastasis response assessed in all treated patien

146 A brain metastasis response was achieved in four (22%; 95%

147 gression, and death caused by progression of brain metastasis, seemed to be improved compared with hi

148 eviously, we reported a protein signature of brain metastasis showing increased ability of brain meta

149 f activated Stat3 is also increased in human brain metastasis specimens when compared with that in th

150 After resection of a brain metastasis, SRS radiosurgery should be considered

151 ancer (NSCLC) to try to improve incidence of brain metastasis, survival, and eventually quality of li

152 In this work, we developed a robust model of brain metastasis that empowers quantitative tracking of

153 However, in patients with brain metastasis, the blood-brain barrier limits its use

154 w discusses recent advances in breast cancer brain metastasis therapy and potential approaches for su

155 d validated in a cohort of 128 patients with brain metastasis treated at the Cross Cancer Institute (

156 mouse model of HER2-amplified breast cancer brain metastasis using an orthotopic xenograft of BT474

157 A nomogram to predict brain metastasis was constructed and validated in a coho

158 Brain metastasis was the most common site of failure.

159 for the correct identification of recurrent brain metastasis were evaluated by receiver-operating-ch

160 disorders or psychosis, substance abuse, or brain metastasis were excluded.

161 th a constitutively activated Stat3 enhanced brain metastasis, whereas blockade of Stat3 activation b

162 -713 in the intracerebrally induced model of brain metastasis, which was significantly greater than t

163 enriched patient population at high risk for brain metastasis will facilitate the design of trials ai

164 eir kind that provide insight into targeting brain metastasis with stem-cell mediated delivery of pro

165 ent (observation group, 46 patients) for the brain metastasis, with median follow-up of 48 weeks and

166 rvival in two murine models of breast cancer brain metastasis, without any apparent local or systemic